Latest Breaking News On - About travere - Page 1 : vimarsana.com

Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy

First non-immunosuppressive therapy for the treatment of IgA nephropathy approved in Europe Conditional marketing authorization is based on statistically significant and clinically meaningful.

New zealandEmmanuelle lecomte brissetThomas hutterDeric dubeUniversity hospitalEuropean commissionTravere therapeutics incFresenius medical careExchange commissionEuropean unionCommittee for medicinal products human useClinical immunologyMedicinal productsHuman useTravere therapeuticsIga nephropathy

Travere Therapeutics Submits Supplemental New Drug Application to the U S Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN)

Submission is based on 2-year confirmatory results from the Phase 3 PROTECT Study in which FILSPARI demonstrated a significant reduction in proteinuria, preservation of kidney function and a generally.

Deric dubeTravere therapeutics incDrug administrationEuropean commissionEuropean unionEuropean medicines agencyCommittee for medicinal products human useExchange commissionNew drug applicationMedicinal productsHuman useAbout travereTravere therapeuticsImportant safetyEndothelin receptor antagonistsUpper limit

Travere Therapeutics, Inc : Travere Therapeutics Submits Supplemental New Drug Application to the U S Food and Drug Administration Seeking Full Approval of FILSPARI (sparsentan) for the Treatment of IgA Nephropathy (IgAN)

Travere Therapeutics, Inc : Travere Therapeutics Submits Supplemental New Drug Application to the U S Food and Drug Administration Seeking Full Approval of FILSPARI (sparsentan) for the Treatment of IgA Nephropathy (IgAN)
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Stefan klotterDeric dubeDrug administrationEuropean unionTravere therapeutics incExchange commissionCommittee for medicinal products human useEuropean commissionEuropean medicines agencyNew drug applicationMedicinal productsHuman useAbout travereTravere therapeuticsImportant safetyEndothelin receptor antagonists

Travere Therapeutics to Present at the 2022 Jefferies Healthcare Conference

02.06.2022 - SAN DIEGO, June 02, 2022 (GLOBE NEWSWIRE) - Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Company management will present at the 2022 Jefferies Healthcare Conference on Thursday, June 9, 2022 at 10:30 a.m. ET. A live webcast will .

Chris clineInvestor relations corporate communicationsAbout travereTravere therapeuticsVice presidentInvestor relations

Travere Therapeutics and Vifor Pharma Announce Licensing Agreement for the Commercialization of Sparsentan in Europe, Australia and New Zealand

Travere Therapeutics and Vifor Pharma Announce Licensing Agreement for the Commercialization of Sparsentan in Europe, Australia and New Zealand
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.

United statesNew zealandDeric dubeVifor pharmaJulien vignotChris clineAbbas hussainNathalie ponnierLigand pharmaceuticalsSwiss stock exchangeTravere therapeutics incGlobal head corporate communicationsSwiss exchangeExchange commissionVifor pharma groupInvestor relations corporate communications